Ad Scientiam
PrivateLast Round
VC Round
Nov 5, 2023
Company Overview
Ad Scientiam is a digital health company that develops and validates digital biomarkers for the continuous monitoring of severe and debilitating chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ad Scientiam Comparables
Compare Ad Scientiam with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Altoida, Inc. | 87% | |
| Koneksa Health | 83% | |
| Neurotrack Technologies, Inc. | 78% | |
Ad Scientiam Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 5, 2023 | ||||
| VC Round | Jul 13, 2017 |
Ad Scientiam Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TechLife Capital | VC Round |
| Bpifrance | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 31, 2026
Monthly visitors grew 165% MoM, reaching 961.
- Nov 5, 2023
$5.4M round led by TechLife Capital
Ad Scientiam Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ad Scientiam's valuation, stock price, and market status.